ZEFAZONE Drug Patent Profile

Which patents cover Zefazone, and what generic alternatives are available?

Zefazone is a drug marketed by Pharmacia And Upjohn and is included in two NDAs.

The generic ingredient in ZEFAZONE is cefmetazole sodium. There are three drug master file entries for this compound. Additional details are available on the cefmetazole sodium profile page.

Summary for ZEFAZONE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	53
Patent Applications:	523
DailyMed Link:	ZEFAZONE at DailyMed

US Patents and Regulatory Information for ZEFAZONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	ZEFAZONE	cefmetazole sodium	INJECTABLE;INJECTION	050637-001	Dec 11, 1989		DISCN	Yes	No
Pharmacia And Upjohn	ZEFAZONE IN PLASTIC CONTAINER	cefmetazole sodium	INJECTABLE;INJECTION	050683-002	Dec 29, 1992		DISCN	Yes	No
Pharmacia And Upjohn	ZEFAZONE	cefmetazole sodium	INJECTABLE;INJECTION	050637-002	Dec 11, 1989		DISCN	Yes	No
Pharmacia And Upjohn	ZEFAZONE IN PLASTIC CONTAINER	cefmetazole sodium	INJECTABLE;INJECTION	050683-001	Dec 29, 1992		DISCN	Yes	No

ZEFAZONE (Market Dynamics and Financial Trajectory): Revenue Exposure, Competitive Threats, and IP/Regulatory Headwinds

Last updated: August 1, 2026

ZEFAZONE’s market dynamics and financial trajectory cannot be profiled from verifiable public sources because “ZEFAZONE” is not uniquely identifiable to a specific, FDA-regulated drug product (active ingredient, dosage form, sponsor, NDC, or Orange Book/Biologics License context). Without a uniquely mapped drug identity, any attempt to quantify revenue, exclusivity, pricing pressure, generic/biosimilar risk, or litigation and settlement effects would be non-actionable.

Key blocker

• No reliable linkage exists in the public record to map “ZEFAZONE” to a specific active ingredient and FDA product listing (Orange Book, Drugs@FDA labels, or BLA context), which is required to build a fact-based financial and competitive trajectory.

If a different drug name or an identified active ingredient / sponsor / dosage form is provided, a full market-and-patent profile can be produced with revenue exposure, exclusivity timelines, Paragraph IV risk, and litigation/regulatory milestones.